Dr.SleepRoch said:The GIP arm is doing real work rather than padding the label.
Careful with treating an unchanged LDL-C as a failure. If ApoB and triglycerides both fell, the particle picture improved regardless of what the calculated LDL says.
Happy to go further on any of that.
Adding the numbers, since they settle part of this. Practical numbers: half-life about 5 days, steady state 3 to 4 weeks, ladder 2.5 / 5 / 7.5 / 10 / 12.5 / 15mg, and the maintenance doses with published data behind them are 5, 10 and 15mg.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
Dr.KarenChen said:Careful with treating an unchanged LDL-C as a failure.
Coming at Dr.KarenChen’s question from a different direction. Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five. That matters when you are deciding whether a dose step has finished expressing itself.
That is the short version; the long version is somebody else's post.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsFollowing on from LeilaHI — and this may be the naive question:
How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?
Reporting back.
Update: the eight-week restart pattern people described is exactly what happened. I nearly abandoned it at week five.